4D Molecular Therapeutics (NASDAQ:FDMT) Releases Earnings Results, Misses Expectations By $0.04 EPS

by · The Cerbat Gem

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04), Zacks reports. 4D Molecular Therapeutics had a negative return on equity of 37.26% and a negative net margin of 182.34%.The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million.

4D Molecular Therapeutics Stock Performance

FDMT traded up $0.21 during trading on Friday, hitting $10.14. 832,043 shares of the stock were exchanged, compared to its average volume of 698,501. The firm has a 50 day simple moving average of $9.38 and a 200 day simple moving average of $9.49. The firm has a market cap of $530.12 million, a price-to-earnings ratio of -3.95 and a beta of 2.77. 4D Molecular Therapeutics has a 1 year low of $3.00 and a 1 year high of $12.34.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. grew its position in shares of 4D Molecular Therapeutics by 21.0% during the 4th quarter. Invesco Ltd. now owns 153,142 shares of the company’s stock worth $1,149,000 after buying an additional 26,563 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of 4D Molecular Therapeutics by 62.6% in the fourth quarter. XTX Topco Ltd now owns 65,022 shares of the company’s stock valued at $488,000 after acquiring an additional 25,039 shares in the last quarter. Virtus Investment Advisers LLC purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth about $184,000. Susquehanna Portfolio Strategies LLC purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth about $77,000. Finally, Tudor Investment Corp ET AL grew its holdings in 4D Molecular Therapeutics by 23.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 31,815 shares of the company’s stock worth $239,000 after acquiring an additional 6,048 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Chardan Capital reiterated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Barclays assumed coverage on shares of 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

Get Our Latest Research Report on 4D Molecular Therapeutics

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Further Reading